Choosing RX over M&A -- anyone recommend this?

I realize that just because RX will most likely be busier than M&A over the next 6 months, that's not a reason to choose RX as a career path... but do some of you think there are reasons that RX is, in general, a more attractive career path than M&A?

Also, if one is doing an M&A internship this summer but might want to transition to RX, is this a seamless transition with respect to recruiting for a FT RX job? Or will RX groups want to see that you have modeling skills/experiences that are specific to RX?

 

From what I’ve heard, Rx works seems less repetitive than M&A and more complex due to the number of different outcomes and parties involved. No first hand experience in it though. Hopefully some generalists out there can give a better answer!

 

Thanks. Yeah, when you say "more complex," that's what I had heard... which is why I was wondering if you needed to demonstrate certain skills/experiences when interviewing for a position in RX.

 

Could they potentially hire more in the current environment?

 

In a similar situation, Have a SA at BB (GS/MS/JPM). Interested in Rx (not just due to current situation) but did not get to interview last rounds with the firm that is strong in Rx due to exploding offer and figured the "Bird in hand is better than two in the bush".

Best way to go about recruiting for RX without annoying current BB and group?

 

I do both M&A and Rx. when working with Rx team, I have the perception the clients give you more credibility as they are going through something they never (almost) experienced before. furthermore, it’s more technical than M&A and the analysis you run are more concrete and less “let’s massage the wacc so we get +10% in the DCF”. having said that, M&A trains you in a great way too, especially during sell side mandates. overall, i believe at jr level they are pretty similar and you should go with the best team in term of exit ops

 

No two restructuring processes are the same. From my understanding, the more technical aspects of modeling include parsing through term sheets in ensuring adequate consideration of covenants as well as sensitizing the company's capital structure for various adjustments. Specific care and focus will be spent in assessing the prevalence of maturity walls, the company's liquidity, and the various interests of creditors.

 
 

Every assumption you make will potentially be brought up in court for your MD to justify/defend. Brings a new level of scrutiny to your modeling, instead of an M&A process where it is often not questioned/analyzed on the same level.

 

I work at one of the firms mentioned below that's generalist between RX and M&A, and I can tell you firsthand, I HATE RX. I absolutely dread getting staffed on RX projects. Don't think RX is more technical quantitatively, it's more technical in terms of reading legal docs. You'll also make a ton of cap tables (not hard). Yes every RX is different but so is every M&A deal imo, especially if you only work for 2-3 years on the sell side. Just my opinion. RX is not for everyone but some people do really like it

 

Can anyone explain how you actually recruit for RX? I know it's kind of a stupid question, but when I was recruiting for SA I felt like I was just generally recruiting for 'banking' and I ended up doing all my interviews with M&A teams. Do these places post different jobs for RX? Did I miss something when filling out apps on all my portals? I feel like I was just shoved into M&A rather than actually choosing it

 

You have to recruit separately for RX team at HL, Evercore, Greenhill, Gugg etc

Moelis and PWP have generalist program, so if you go there you'll get both M&A and RX exposure

Lazard from what I heard has generalist internship then you get placed for FT

 

I've only done 1 RX deal, but it was very interesting. Sell side can be repetitive for some, but I love it. I think if you're more interested in how markets operate (i.e interest rates) than RX may be a better fit. I've talked to some analyst at HL and they made the switch form CF to RX and love it. A lot of rules are involved, but definitely interests people. Also, you don't really have to worry about the deal falling apart, RX deals need to get done in a set amount of time ordered by a judge. There is also distressed M&A in RX if M&A is still of interest to you

 

Evidently work can be seen as more interesting to some people, but also a more specific/niche field. At the end of the day it's down to what you value - will an EB RX gig get you that top PE exit that you wanted? Possibly, but it's gonna be harder than a top M&A group, where your optionality set is much bigger.

 

disagree with your conclusion. EB RX gigs give you more optionality in opening up an easier path to distressed recruiting (which is doable but much harder from an M&A seat), while still giving you the same options of buyout PE, growth equity, corp dev, etc.

 

It is difficult to make a direct comparison for PE/non-distressed recruiting since at the end of the day, EB RX analysts self-select to distressed funds. Still, your work is intrinsically not geared toward PE sponsors, modelling and admin work for conventional acquisitions (for conventional PE recruiting). Other than PE, I think it's in general a stretch to argue a RX group is at the same level of exit optionality (L/S equity HFs, corp dev, industry-specific stuff) compared with an M&A group of the same pedigree. After all, your work is geared toward a very specific product at a very specific period of a company/investor's lifecycle. Then again, there's nothing conclusive anyone can say since the dataset is skewed away from non-distressed options due to self-selecting.

 
Most Helpful

agree that there's a self-selecting effect. I meant more just that from a pure optionality standpoint on what's being presented to you, my peers in RX have not found that recruiting efforts to PE, L/S, corp-dev, etc were made more difficult due to their RX background. On the other hand it's more of an uphill battle to join a distressed shop from an M&A background - not impossible, of course, but there's a strong preference for RX analysts due to the relevant background experience.

 

Quia eos nisi ut dolor optio. Possimus beatae mollitia suscipit repudiandae laboriosam voluptatem placeat. Eius mollitia et rerum eveniet est.

 

Tempora optio maiores nihil itaque ut laborum facere. Modi sapiente in nisi assumenda sunt cupiditate. Molestiae mollitia voluptatem quia mollitia sapiente dicta. Ut modi placeat vitae vel eum. Nam eius accusantium inventore cumque perferendis corporis. Labore praesentium ipsum id facilis. Corporis tempore rerum dolores provident incidunt pariatur libero repellendus.

Omnis perspiciatis id ea molestiae rerum. Ullam eius laudantium ex ut. Eveniet dolores assumenda sequi praesentium.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (86) $261
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (145) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”